Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure
Published Mar 31, 2016 · K. Jujo, Katsumi Saito, I. Ishida
ESC Heart Failure
87
Citations
2
Influential Citations
Abstract
Loop diuretics are first‐line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin–angiotensin system activation. We tested whether tolvaptan, a vasopressin V2‐receptor antagonist, could reduce unfavourable furosemide‐induced effects during CHF treatment.
Study Snapshot
Key takeawayTolvaptan may reduce unfavourable effects of furosemide in acute heart failure treatment, potentially improving renal function and neurohumoral effects.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.